Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab in Severe Steroid-Dependent Asthma
NCT02528214Phase 3Completed
- Sponsor
- Sanofi
- Start
- Oct 2015
- Primary completion
- Sep 2017
- Modality
- Monoclonal Antibodies
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial in asthma comparing Dupilumab 300 mg q2w with Placebo q2w (2 arms). Primary endpoint: Percentage Reduction From Baseline in Oral Corticosteroids (OCS) Dose at Week 24 While Maintaining Asthma Control. Started Oct 2015; status: completed.
02
Drugs
03
Conditions
asthma
Beyond the preview
Go deeper on NCT02528214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02528214.